Pancreatic ductal adenocarcinoma (PDAC) is one of the tumors with the highest mortality, for which survival has hardly changed in the last 40 years. This high mortality is due to the lack of tests that would allow an early diagnosis and the fact that current treatments are not very effective. Liquid biopsy (LB) represents an interesting tool that can help in early diagnosis, treatment selection, disease monitoring, evaluation of the response and prognosis.
It is a minimally invasive and risk-free procedure that can detect both the presence of genetic material from the tumor and circulating tumor cells (CTCs) in the blood and in other bodily fluids, and therefore distantly reflect the global status of the disease. Read more . . .